MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Cognitive profiles at presentation and subsequent cognitive decline in PD-MCI.

S. Mirza, S. Duff-Canning, M. Masellis, C. Marras (Toronto, Canada)

Meeting: 2022 International Congress

Abstract Number: 1235

Keywords: Cognitive dysfunction, Parkinson’s

Category: Parkinson's Disease: Cognitive functions

Objective: To determine cognitive profiles in a Parkinson‘s Disease-Mild Cognitive Impairment (PD-MCI) cohort, and study the relationship between baseline cognitive phenotype and subsequent cognitive decline.

Background: The range of cognitive deficits in PD-MCI is variable; identification of patterns of these deficits in PD-MCI may aid to predict subsequent decline and guide therapeutic interventions to improve the natural pathologic course.

Method: 139 persons with PD-MCI,(diagnosis:MDS Task Force Level 2 criteria) were recruited from 6 movement disorders clinics and followed up annually for 5 years. A comprehensive cognitive test battery of10 tests was administered at all visits. Cognitive profiles were determined at baseline by cluster analyses. We calculated a global cognitive zscore at all visits by averaging zscores for all tests, and a Reliable Cognitive Change (RCC) related to the baseline per test (0=Change absent,1=present) at each follow-up visit. RCC was calculated using the reliable change index method, which takes into account measurement error, practice effects and regression to the mean and determines whether an observed change falls outside the 95% CI for change based on normative samples. Cognitive decline was determined by 1.change in global cognitive zscore (linear mixed-effects models), and 2. time to first RCC in any cognitive test (Survival analysis). All analyses were adjusted for age, sex and education.

Results: Mean age of the sample was 70.2±6.2 years, mean education was 15.7±2.8 years, and 34% were women. We identified 4 clusters of cognitive profiles at baseline, characterized by 1.executive(n=44), 2.visuospatial(n=26), 3.executive & visuospatial(n=50), and 4.global cognitive impairment(n=19). Compared to cluster 1, those in cluster 3 (β=-0.63, 95%CI: -0.84,-0.41,p-value <0.0010) and 4 (β=-1.74, 95%CI: -2.03,-1.45, p-value <0.001) showed a significant decline in global cognitive z-scores. Of the 117 individuals included in the survival analysis, 63 developed an RCC over 1074.7 personyears. Persons in cluster 3 (hazard ratio=1.82, 95%CI: 0.99, 3.35), p-value 0.052; mean time to event=2.3 yrs) and 4 (hazard ratio=2.42, 95%CI: 0.99, 5.92, p-value 0.052; mean time to event=1.7 yrs) showed a trend of having a higher risk of developing an RC compared to cluster 1(mean time to event=2.8 yrs).

Conclusion: Identification of cognitive profiles in PD-MCI patients may help predict their cognitive trajectory overtime.

To cite this abstract in AMA style:

S. Mirza, S. Duff-Canning, M. Masellis, C. Marras. Cognitive profiles at presentation and subsequent cognitive decline in PD-MCI. [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/cognitive-profiles-at-presentation-and-subsequent-cognitive-decline-in-pd-mci/. Accessed May 15, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/cognitive-profiles-at-presentation-and-subsequent-cognitive-decline-in-pd-mci/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley